Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Tolerability of LY3502970 in Healthy Overweight and Obese Participants
NCT05841238Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of orforglipron in obesity (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point of LY3502970 in Fasted State, Maximum Observed Concentration of LY3502970 in Fasted State and 1 more. Started Apr 2023; status: completed.
02
Drugs
orforglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05841238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841238.